Lymphomas
MK2140-011:A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
- Details
ClinicalTrials.gov ID:
NCT06890884
Diagnosis Type:
NA
USOR Number:
- Address
,
P: